Combination therapy with oncolytic viruses and immune checkpoint inhibitors
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combination therapy with oncolytic viruses and immune checkpoint inhibitors
Authors
Keywords
-
Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume -, Issue -, Pages 1-18
Publisher
Informa UK Limited
Online
2020-02-18
DOI
10.1080/14712598.2020.1729351
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics
- (2019) Zong Sheng Guo et al. Journal for ImmunoTherapy of Cancer
- Chimeric tumor modeling reveals role of partial PDL1 expression in resistance to virally induced immunotherapy
- (2019) Mee Y. Bartee et al. Journal for ImmunoTherapy of Cancer
- A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)
- (2019) Jean-Pascal Machiels et al. Journal for ImmunoTherapy of Cancer
- Oncolytic Virus-based Cytokine Expression to Improve Immune Activity in Brain and Solid Tumors
- (2019) Taylor M. Pearl et al. Molecular Therapy-Oncolytics
- PD-1 blockade following isolated limb perfusion with vaccinia virus prevents local and distant relapse of soft-tissue sarcoma
- (2019) Henry G Smith et al. CLINICAL CANCER RESEARCH
- Prediction of response to pelareorep plus pembrolizumab in pancreatic ductal adenocarcinoma (PDAC).
- (2019) Christos Fountzilas et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunological impact of canerpaturev (C-REV, formerly HF10), an oncolytic viral immunotherapy, with or without ipilimumab (Ipi) for advanced solid tumor patients (pts).
- (2019) Takayuki Nakayama et al. JOURNAL OF CLINICAL ONCOLOGY
- Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma
- (2019) Lukasz Kuryk et al. JOURNAL OF MEDICAL VIROLOGY
- Optimizing oncolytic virotherapy in cancer treatment
- (2019) Kevin Harrington et al. NATURE REVIEWS DRUG DISCOVERY
- Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
- (2019) Robert H. I. Andtbacka et al. Journal for ImmunoTherapy of Cancer
- Molecular and metabolic pathways mediating curative treatment of a non-Hodgkin B cell lymphoma by Sindbis viral vectors and anti-4-1BB monoclonal antibody
- (2019) Minjun Yu et al. Journal for ImmunoTherapy of Cancer
- Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses
- (2019) Maria Cristina Ballesteros-Briones et al. MOLECULAR THERAPY
- Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1
- (2019) Suzanne Thomas et al. Journal for ImmunoTherapy of Cancer
- Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade
- (2019) Tala Shekarian et al. Science Translational Medicine
- Recombinant Poliovirus for Cancer Immunotherapy
- (2018) Matthias Gromeier et al. Annual Review of Medicine
- Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors
- (2018) Tobias Speck et al. CLINICAL CANCER RESEARCH
- Armed oncolytic viruses: A kick-start for anti-tumor immunity
- (2018) J.F. de Graaf et al. CYTOKINE & GROWTH FACTOR REVIEWS
- PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy
- (2018) Dmitriy Zamarin et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma
- (2018) Frederick F. Lang et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
- (2018) Jason Chesney et al. JOURNAL OF CLINICAL ONCOLOGY
- Superagonist IL-15-armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade
- (2018) Stacy J. Kowalsky et al. MOLECULAR THERAPY
- Recurrent Glioblastoma Treated with Recombinant Poliovirus
- (2018) Annick Desjardins et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy
- (2018) Marie-Claude Bourgeois-Daigneault et al. Science Translational Medicine
- Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade
- (2018) Adel Samson et al. Science Translational Medicine
- The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials
- (2018) Ellen Suder et al. Human Vaccines & Immunotherapeutics
- Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus–Driven Production of a Bispecific T-cell Engager
- (2018) Anna Wing et al. Cancer Immunology Research
- TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade
- (2018) V. Cervera-Carrascon et al. OncoImmunology
- Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus
- (2018) Nicola E. Annels et al. Molecular Therapy-Oncolytics
- Systemically Administered Sindbis Virus in Combination with Immune Checkpoint Blockade Induces Curative Anti-tumor Immunity
- (2018) Iris Scherwitzl et al. Molecular Therapy-Oncolytics
- A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma
- (2018) Devalingam Mahalingam et al. Cancers
- Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer
- (2018) Ahmed Mostafa et al. Cancers
- Recombinant oncolytic poliovirus combined with checkpoint blockade for breast cancer therapy.
- (2018) Jeremy Force et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
- (2018) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- T Cell–Inflamed versus Non-T Cell–Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection
- (2018) Jonathan A. Trujillo et al. Cancer Immunology Research
- Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment
- (2018) Amanda Rosewell Shaw et al. Frontiers in Immunology
- Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials
- (2018) Jonathan G. Pol et al. OncoImmunology
- An Oncolytic Virus Expressing a T-cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells
- (2018) Joshua D. Freedman et al. CANCER RESEARCH
- Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy
- (2018) Carmela Passaro et al. CLINICAL CANCER RESEARCH
- Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
- (2018) Ezra E W Cohen et al. LANCET
- ATIM-24. INTERIM RESULTS OF A PHASE II MULTICENTER STUDY OF THE CONDITIONALLY REPLICATIVE ONCOLYTIC ADENOVIRUS DNX-2401 WITH PEMBROLIZUMAB (KEYTRUDA) FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192)
- (2018) Gelareh Zadeh et al. NEURO-ONCOLOGY
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model
- (2018) Lukasz Kuryk et al. OncoImmunology
- Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy
- (2017) K R Kelly et al. LEUKEMIA
- Solid Tumor Immunotherapy with T Cell Engager-Armed Oncolytic Viruses
- (2017) Eleanor M. Scott et al. MACROMOLECULAR BIOSCIENCE
- Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy
- (2017) Nicholas M. Durham et al. MOLECULAR THERAPY
- Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer
- (2017) Amanda Rosewell Shaw et al. MOLECULAR THERAPY
- Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma
- (2017) Maria-Carmela Speranza et al. NEURO-ONCOLOGY
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas
- (2017) Wanlu Du et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Oncolytic viruses: adenoviruses
- (2017) Julia Niemann et al. VIRUS GENES
- Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain
- (2017) Manisha Singh et al. Nature Communications
- Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity
- (2017) Dmitriy Zamarin et al. Nature Communications
- Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy
- (2017) Zuqiang Liu et al. Nature Communications
- Review: Oncolytic virotherapy, updates and future directions
- (2017) Christos Fountzilas et al. Oncotarget
- Customized Viral Immunotherapy for HPV-Associated Cancer
- (2017) Matthew J. Atherton et al. Cancer Immunology Research
- Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models
- (2017) William K. Decker et al. Frontiers in Immunology
- Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators
- (2017) Arthur Dyer et al. Molecular Therapy-Oncolytics
- Prospects for combined use of oncolytic viruses and CAR T-cells
- (2017) Adam Ajina et al. Journal for ImmunoTherapy of Cancer
- Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection
- (2017) Rocio Garcia-Carbonero et al. Journal for ImmunoTherapy of Cancer
- Genetically Engineered Vaccinia Viruses As Agents for Cancer Treatment, Imaging, and Transgene Delivery
- (2017) Dana Haddad Frontiers in Oncology
- 1066PCOMBINATION OF A NOVEL ONCOLYTIC IMMUNOTHERAPEUTIC AGENT, COXSACKIEVIRUS A21 AND PD-1 BLOCKADE SIGNIFICANTLY REDUCES TUMOR GROWTH AND IMPROVES SURVIVAL IN AN IMMUNE COMPETENT MOUSE MELANOMA MODEL
- (2017) D. Shafren et al. ANNALS OF ONCOLOGY
- OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.
- (2017) Robert Hans Ingemar Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes
- (2017) Nalini Marino et al. PLoS One
- Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer
- (2016) Federica Cappuccini et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy
- (2016) E Ilett et al. GENE THERAPY
- Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
- (2016) Igor Puzanov et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses
- (2016) Karishma Rajani et al. MOLECULAR THERAPY
- Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma
- (2016) Mikko Siurala et al. MOLECULAR THERAPY
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer
- (2016) Lily Francis et al. Oncotarget
- Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition
- (2016) Patricia Kleinpeter et al. OncoImmunology
- Systemic therapy with oncolytic myxoma virus cures established residual multiple myeloma in mice
- (2016) Eric Bartee et al. Molecular Therapy-Oncolytics
- Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers
- (2016) Tuuli Ranki et al. Journal for ImmunoTherapy of Cancer
- Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia
- (2015) W. Shen et al. BLOOD
- Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy
- (2015) J. J. Rojas et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy
- (2015) F. J. Kohlhapp et al. CLINICAL CANCER RESEARCH
- Arming oncolytic viruses to leverage antitumor immunity
- (2015) Tanja D de Gruijl et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling
- (2015) Julia V. Cockle et al. NEURO-ONCOLOGY
- Oncolytic viruses: From bench to bedside with a focus on safety
- (2015) Pascal RA Buijs et al. Human Vaccines & Immunotherapeutics
- Virotherapy with a Semliki Forest Virus–Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade
- (2015) José I. Quetglas et al. Cancer Immunology Research
- CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy
- (2015) Zuqiang Liu et al. OncoImmunology
- Armed Oncolytic Virus Enhances Immune Functions of Chimeric Antigen Receptor-Modified T Cells in Solid Tumors
- (2014) N. Nishio et al. CANCER RESEARCH
- The Common -Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands
- (2014) A. L. Kinter et al. JOURNAL OF IMMUNOLOGY
- CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy
- (2014) Christine E Engeland et al. MOLECULAR THERAPY
- Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
- (2014) D. Zamarin et al. Science Translational Medicine
- Consensus guidelines for the detection of immunogenic cell death
- (2014) Oliver Kepp et al. OncoImmunology
- Immunotherapeutic Potential of Oncolytic Vaccinia Virus
- (2014) Steve H. Thorne Frontiers in Oncology
- Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer
- (2013) Kouichirou Aida et al. CANCER SCIENCE
- Adenovirus Expressing Both Thymidine Kinase and Soluble PD1 Enhances Antitumor Immunity by Strengthening CD8 T-cell Response
- (2013) Seung-Pil Shin et al. MOLECULAR THERAPY
- T-cell Engager-armed Oncolytic Vaccinia Virus Significantly Enhances Antitumor Therapy
- (2013) Feng Yu et al. MOLECULAR THERAPY
- Oncolytic Virus and Anti-4-1BB Combination Therapy Elicits Strong Antitumor Immunity against Established Cancer
- (2012) L. B. John et al. CANCER RESEARCH
- Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients
- (2012) S. Pesonen et al. CANCER RESEARCH
- Attenuated Oncolytic Measles Virus Strains as Cancer Therapeutics
- (2012) P. Msaouel et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Immunotherapeutic Synergy Between Anti-CD137 mAb and Intratumoral Administration of a Cytopathic Semliki Forest Virus Encoding IL-12
- (2012) José I Quetglas et al. MOLECULAR THERAPY
- Combined vaccination and immunostimulatory antibodies provides durable cure of murine melanoma and induces transcriptional changes associated with positive outcome in human melanoma patients
- (2012) A.J. Robert McGray et al. OncoImmunology
- Oncolytic adenoviruses
- (2012) Vincenzo Cerullo et al. OncoImmunology
- Chemokine Expression From Oncolytic Vaccinia Virus Enhances Vaccine Therapies of Cancer
- (2011) Jun Li et al. MOLECULAR THERAPY
- A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer
- (2010) M. P. Lolkema et al. CLINICAL CANCER RESEARCH
- Identification of Genetically Modified Maraba Virus as an Oncolytic Rhabdovirus
- (2010) Jan Brun et al. MOLECULAR THERAPY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma
- (2009) Howard L. Kaufman et al. ANNALS OF SURGICAL ONCOLOGY
- Host Lymphodepletion Enhances the Therapeutic Activity of an Oncolytic Vaccinia Virus Expressing 4-1BB Ligand
- (2009) H. S. Kim et al. CANCER RESEARCH
- Therapeutic and Tumor-specific Immunity Induced by Combination of Dendritic Cells and Oncolytic Adenovirus Expressing IL-12 and 4-1BBL
- (2009) Jing-Hua Huang et al. MOLECULAR THERAPY
- Directed Evolution Generates a Novel Oncolytic Virus for the Treatment of Colon Cancer
- (2008) Irene Kuhn et al. PLoS One
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started